Open AccessThe Potential Role of Genomic Signature in Stage II Relapsed Colorectal Cancer (CRC) Patients: A Mono-Institutional Study
Author(s) -
Michela Roberto,
Giulia Arrivi,
Emanuela Pilozzi,
A Montori,
Genoveffa Balducci,
Paolo Mercantini,
Andréa Laghi,
Debora Ierinò,
Martina Panebianco,
Daniele Marinelli,
Silverio Tomao,
Paolo Marchetti,
Federica Mazzuca
Publication year - 2022
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s342612
Subject(s) - kras , medicine , colorectal cancer , oncology , mlh1 , chemotherapy , frameshift mutation , stage (stratigraphy) , cancer , mutation , gene , genetics , biology , dna mismatch repair , paleontology
The absolute benefit of adjuvant chemotherapy in stage II CRC is only 3-4%. The identification of biomarkers through molecular profiling could identify patients who will more benefit from adjuvant chemotherapy.